This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/drugbank/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n22http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00092
rdf:type
n3:Drug
n3:description
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
n3:generalReferences
# Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;5(7):623-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16865867 # Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006 Jun;54(6):1099-101. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16713481 # Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006 Apr;5(4):339-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16673801 # American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Alefacept; [updated 2014 Jan 30; cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=9&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232900
n3:group
withdrawn approved
n3:halfLife
~270 hours
n3:indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
owl:sameAs
n16:DB00092 n17:DB00092
dcterms:title
Alefacept
adms:identifier
n5:PA164748040 n6:Alefacept n20:DB00092
n3:mechanismOfAction
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.
n3:packager
n14:271B44AC-363D-11E5-9242-09173F13E4C5 n14:271B44AD-363D-11E5-9242-09173F13E4C5 n14:271B44AE-363D-11E5-9242-09173F13E4C5
n3:synonym
ASP0485
n3:toxicity
While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.
n9:hasAHFSCode
n10:84-92-00
n12:hasConcept
n13:M0374901
foaf:page
n19:amevive.htm n21:alefacept.html
n3:Molecular-Formula
n7:271B44B3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n7:271B44B2-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n11:L04AA15
n3:absorption
Bioavailability after IM administration is 63%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
222535-22-0
n3:category
n3:containedIn
n22:271B44AF-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n7:271B44B0-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n7:271B44B1-363D-11E5-9242-09173F13E4C5